Market Overview

Lipocine Showered With Good News Recently

Lipocine Showered With Good News Recently

Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks.

September 26: Positive Top-Line Results

The company announced results from a Phase 2b clinical study of its LPCN 1111, a novel oral testosterone replacement therapy (TRT) product candidate.

The purpose of the study was to determine the Phase 3 dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males.

The company said that results from the trial were met and good dose-response relationship was observed. The therapy was also well tolerated with no drug-related severe or serious adverse events reported.

October 7: Patent Lawsuit Victory, Buy Rating Established

Lipocine said it won a patent infringement lawsuit against Clarus Therapeutics.

A U.S. court granted Lipocine's motion to dismiss the lawsuit which was filed by Clarus Therapeutics who claimed that LPCN 1021 infringes on its own patent.

LPCN 1021 is Lipocine's oral testosterone product candidate in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.

On the same day, H.C. Wainwright's Corey Davis initiated coverage of Lipocine with a Buy rating and $25 price target, implying a potential upside of around 500 percent.

Davis highlighted the company's competitive advantage over its peers - its drug delivering technology called Lip'ral.

Price Action

Lipocine's stock opened for trading on Monday, September 26, at $4.93 after closing at $3.94 the prior trading day..

From September 27 through October 6, the stock traded as low as $3.95 and as high as $4.58.

Friday's patent win announcement and bullish analyst note reaffirmed the bullish momentum. Shares opened for trading at $5.20 (after closing at $4.17 on Thursday) and hit an intra-day high of $5.90 before closing the day at $5.41.

Shares opened for trading at $5.73 today, but gave up the gains after 30 minutes of trading and were last seen at $5.39, down 0.37 percent on the day.

Posted-In: Clarus Therapeutics Corey Davis H.C. WainwrightBiotech Health Care Movers Trading Ideas General Best of Benzinga


Related Articles (LPCN)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

American Eagle Outfitters Could Soar In The Second Half Of 2016; BMO Upgrades

SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower